Evidence map›Paper›PMID 33341891›Full record

ArticleHealth policy and planning2021

How to reduce household costs for people with tuberculosis: a longitudinal costing survey in Nepal.

Suman Chandra Gurung, Bhola Rai, Kritika Dixit, Eve Worrall, Puskar Raj Paudel, Raghu Dhital, Manoj Kumar Sah, Ram Narayan Pandit, Tara Prasad Aryal, Govinda Majhi and 14 more

Abstract read
In one paragraph

Article in Health policy and planning, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Suman Chandra GurungBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Bhola RaiBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Kritika DixitBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Eve WorrallDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.ORCID 0000-0001-9147-3388
Puskar Raj PaudelBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Raghu DhitalBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Manoj Kumar SahBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Ram Narayan PanditBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Tara Prasad AryalBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Govinda MajhiBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Tom WingfieldDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
Bertie SquireDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
Knut LönnrothKarolinska Institutet, Department of Global Public Health, 171 77, Stockholm, Sweden.
Jens W LevyKNCV Tuberculosis Foundation, Maanweg 174, 2516 AB, Den Haag, the The Netherlands.
Kerri VineyKarolinska Institutet, Department of Global Public Health, 171 77, Stockholm, Sweden.
Job van RestKNCV Tuberculosis Foundation, Maanweg 174, 2516 AB, Den Haag, the The Netherlands.
Andrew RamsayUniversity of St Andrews, College Gate St Andrews, KY16 9AJ, UK.
Rafaely Marcia Santos da CostaOswaldo Cruz Foundation, Centro de Pesquisa Aggeu Magalhaes, Av. Professor Moraes Rego, s/n - Cidade Universitária - Recife/PE, CEP 50.740-465, Brazil.
Buddha BasnyatOxford University Clinical Research Unit, P. O. Box 26500, Kathmandu, Nepal.
Anil ThapaNational Tuberculosis Control Centre, Thimi, Bhaktapur, Nepal.
Gokul MishraBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Julia Moreira PescariniOswaldo Cruz Foundation, Centro de Integracao de Dados e Conhecimentos para Saude, Rua Mundo, 121, Trobogy, Salvador - Bahia, CEP 41745-715, Brazil.ORCID 0000-0001-8711-9589
Maxine CawsBirat Nepal Medical Trust: Lazimpat, Ward No. 2, Kathmandu, Nepal.
Noemia Teixeira de Siqueira-FilhaDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.

Funding

Medical Research Council MR/K007467/1Medical Research Council MR/V004832/1
6 · The paper itself

Abstract

The aim of this study was to compare costs and socio-economic impact of tuberculosis (TB) for patients diagnosed through active (ACF) and passive case finding (PCF) in Nepal. A longitudinal costing survey was conducted in four districts of Nepal from April 2018 to October 2019. Costs were collected using the WHO TB Patient Costs Survey at three time points: intensive phase of treatment, continuation phase of treatment and at treatment completion. Direct and indirect costs and socio-economic impact (poverty headcount, employment status and coping strategies) were evaluated throughout the treatment. Prevalence of catastrophic costs was estimated using the WHO threshold. Logistic regression and generalized estimating equation were used to evaluate risk of incurring high costs, catastrophic costs and socio-economic impact of TB over time. A total of 111 ACF and 110 PCF patients were included. ACF patients were more likely to have no education (75% vs 57%, P = 0.006) and informal employment (42% vs 24%, P = 0.005) Compared with the PCF group, ACF patients incurred lower costs during the pretreatment period (mean total cost: US$55 vs US$87, P < 0.001) and during the pretreatment plus treatment periods (mean total direct costs: US$72 vs US$101, P < 0.001). Socio-economic impact was severe for both groups throughout the whole treatment, with 32% of households incurring catastrophic costs. Catastrophic costs were associated with 'no education' status [odds ratio = 2.53(95% confidence interval = 1.16-5.50)]. There is a severe and sustained socio-economic impact of TB on affected households in Nepal. The community-based ACF approach mitigated costs and reached the most vulnerable patients. Alongside ACF, social protection policies must be extended to achieve the zero catastrophic costs milestone of the End TB strategy.

Indexed as

TuberculosisFamily CharacteristicsHumansNepalPovertyPrevalencecase findingcatastrophic costscostsNepalTuberculosis

Identifiers

PMID33341891
PMCPMC8173598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.